<DOC>
	<DOCNO>NCT00332176</DOCNO>
	<brief_summary>The objective study undertake initial evaluation safety , tolerability , antiviral effect , pharmacokinetics celgosivir combination peginterferon alfa-2b ribavirin patient chronic HCV infection .</brief_summary>
	<brief_title>A Study Evaluate Safety , Antiviral Effect , Pharmacokinetics Celgosivir Combination With Peginterferon Alfa-2b Ribavirin Treatment-Naïve Patients With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>1865 year age , inclusive primary diagnosis chronic HCV infection , genotype 1 Interferonbased treatmentnaïve Body Mass Index 18 30 , inclusive patient previously treat Interferonbased therapy patient diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Celgosivir</keyword>
	<keyword>HCV</keyword>
	<keyword>Genotype 1</keyword>
	<keyword>Treatment-naive</keyword>
	<keyword>Early viral kinetics</keyword>
</DOC>